WeTrials
Recruiting

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

What is this study?

This study is testing a new medication called STK-012, both by itself and mixed with standard cancer treatments. Researchers want to see if this new approach can help treat advanced lung cancer more effectively.

Who can participate?

You might be able to join if you have advanced non-small cell lung cancer that has not been treated with full-body therapies before. There are some rules about past treatments and other health conditions to keep you safe.

What will happen?

Depending on the study phase, you will receive either the study medication alone or in combination with standard chemotherapy and immunotherapy drugs. Your health team will monitor you closely throughout the process.

Where and when?

This study is currently recruiting participants at locations in Arizona and California, United States.

Key Points
  • 1Tests a new investigational medication called STK-012
  • 2Focuses on newly diagnosed, advanced lung cancer
  • 3Combines the new drug with standard chemotherapy and immunotherapy

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorNon Small Cell Lung CancerUntreated Advanced NSCLC1st Line NSCLC

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.